We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.16B
AUM Growth
+$298M
Cap. Flow
+$233M
Cap. Flow %
19.99%
Top 10 Hldgs %
67.73%
Holding
38
New
15
Increased
4
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$64.7M
2
IMMU
Immunomedics Inc
IMMU
+$37.1M
3
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$31.3M
4
FOLD
Amicus Therapeutics
FOLD
+$29.5M
5
ARGX icon
argenx
ARGX
+$25.4M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$47.3M
2
QURE icon
uniQure
QURE
+$21.3M
3
ALLK
Allakos
ALLK
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
26
DELISTED
Mersana Therapeutics
MRSN
$8.44M 0.73%
+83,360
New +$9.82M
IMMU
27
CALL
DELISTED
Immunomedics Inc
IMMU
$8.32M 0.72%
+600,000
New +$9.03M
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.42B
$7.61M 0.65%
+764,252
New +$8.31M
AKRO
29
DELISTED
Akero Therapeutics
AKRO
$7.6M 0.65%
+396,695
New +$7.52M
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
$7.6M 0.65%
+3,688,100
New +$8.21M
LITS
31
Lite Strategy Inc
LITS
$32.8M
$7.28M 0.63%
145,655
– –
LJPC
32
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.32M 0.46%
+575,000
New +$4.33M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$4.43M 0.38%
200,000
– –
KNSA icon
34
Kiniksa Pharmaceuticals
KNSA
$5.8B
$3.93M 0.34%
290,577
– –
VYGR icon
35
Voyager Therapeutics
VYGR
$183M
$2.72M 0.23%
+100,000
New +$2.29M
CLRB icon
36
Cellectar Biosciences
CLRB
$20.5M
$2.01M 0.17%
+3,067
New +$2.09M
ELDN icon
37
Eledon Pharmaceuticals
ELDN
$261M
$328K 0.03%
18,021
– –
BIIB icon
38
Biogen
BIIB
$30B
– –
-200,000
Closed -$47.3M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Boxer Capital held 38 positions worth $1.16B, up 35% from $865M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Boxer Capital deployed $233M of net new capital in Q2 2019, opening 15 new positions and adding to 4 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 600,000 shares worth $61.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $21.3M trimmed.

  • Boxer Capital's largest Q2 2019 buy was Spark Therapeutics, Inc. Common Stock: 600,000 shares worth $61.4M.
  • Boxer Capital added most to Immunomedics Inc in Q2 2019, an estimated $37.1M increase.
  • Boxer Capital's biggest Q2 2019 reduction was uniQure, cutting an estimated $21.3M.
  • Boxer Capital fully exited Biogen in Q2 2019, selling an estimated $47.3M.
  • Boxer Capital's ten largest holdings make up 68% of its $1.16B portfolio in Q2 2019.
  • Boxer Capital opened 15 new positions and closed 1 in Q2 2019.
  • Boxer Capital's portfolio value rose 35% quarter-over-quarter to $1.16B.

Based on Boxer Capital's 13F filing for Q2 2019, filed 14 Aug 2019.